Quinoprazine, a powerful inhibitor of Vaccinia virus DNA synthesis (IC50 = 10 μM), exhibits notable antimalarial activity against Plasmodium berghei. Additionally, it demonstrates significant antiprion potency, effectively reducing levels of PrPSc [1]-[5].

Quinoprazine exhibits antimalarial properties against the chloroquine-resistant Plasmodium berghei strain, LN-K65 [1], and impedes Vaccinia Virus infection by obstructing DNA synthesis [2]. As IND2118, it demonstrates significant antiprion efficacy by reducing PrP Sc levels by 76% in dividing cells and 51% in nondividing cells, with reductions over 30% regarded as potent [3] [4]. Moreover, IND2118 has low cytotoxicity, diminishing cell viability by only 25% in dividing cells and 24% in nondividing cells, with reductions below 30% considered safe [3] [4].

Quinoprazine, a 1-alkyl-4-[4-(heterylamino)phenyl]piperazine derivative, effectively suppresses Echinococcus multilocularis larvocyst growth in cotton rats at a dosage of 0.25 g/kg intraperitoneally (i.p.) in a single dose. Furthermore, at oral (p.o.) dosages ranging from 0.2 to 0.5 g/kg, it radically eradicates adult Hymenolepis nana infections in mice, as demonstrated in experimental studies [5].